Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
2003 1
2004 1
2005 1
2006 4
2007 2
2008 2
2009 2
2010 1
2011 2
2012 7
2013 3
2014 6
2015 4
2016 5
2017 3
2018 4
2019 2
2020 4
2021 6
2022 4
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J. Baldominos P, et al. Among authors: agudo j. Cell. 2022 May 12;185(10):1694-1708.e19. doi: 10.1016/j.cell.2022.03.033. Epub 2022 Apr 20. Cell. 2022. PMID: 35447074 Free PMC article.
SOX17 enables immune evasion of early colorectal adenomas and cancers.
Goto N, Westcott PMK, Goto S, Imada S, Taylor MS, Eng G, Braverman J, Deshpande V, Jacks T, Agudo J, Yilmaz ÖH. Goto N, et al. Among authors: agudo j. Nature. 2024 Mar;627(8004):636-645. doi: 10.1038/s41586-024-07135-3. Epub 2024 Feb 28. Nature. 2024. PMID: 38418875
Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
Bagati A, Kumar S, Jiang P, Pyrdol J, Zou AE, Godicelj A, Mathewson ND, Cartwright ANR, Cejas P, Brown M, Giobbie-Hurder A, Dillon D, Agudo J, Mittendorf EA, Liu XS, Wucherpfennig KW. Bagati A, et al. Among authors: agudo j. Cancer Cell. 2021 Jan 11;39(1):54-67.e9. doi: 10.1016/j.ccell.2020.12.001. Epub 2020 Dec 31. Cancer Cell. 2021. PMID: 33385331 Free PMC article.
Targeting cancer cell dormancy.
Agudo J, Aguirre-Ghiso JA, Bhatia M, Chodosh LA, Correia AL, Klein CA. Agudo J, et al. Nat Rev Cancer. 2024 Feb;24(2):97-104. doi: 10.1038/s41568-023-00642-x. Epub 2023 Dec 7. Nat Rev Cancer. 2024. PMID: 38062251 Free PMC article.
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M. Salmon H, et al. Among authors: agudo j. Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012. Immunity. 2016. PMID: 27096321 Free PMC article.
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Hermida-Prado F, et al. Among authors: agudo j. Cancer Res. 2023 Oct 2;83(19):3284-3304. doi: 10.1158/0008-5472.CAN-23-1711. Cancer Res. 2023. PMID: 37450351 Free PMC article.
Quiescent Tissue Stem Cells Evade Immune Surveillance.
Agudo J, Park ES, Rose SA, Alibo E, Sweeney R, Dhainaut M, Kobayashi KS, Sachidanandam R, Baccarini A, Merad M, Brown BD. Agudo J, et al. Immunity. 2018 Feb 20;48(2):271-285.e5. doi: 10.1016/j.immuni.2018.02.001. Immunity. 2018. PMID: 29466757 Free PMC article.
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Keenan TE, et al. Among authors: agudo j. Nat Commun. 2021 Sep 21;12(1):5563. doi: 10.1038/s41467-021-25769-z. Nat Commun. 2021. PMID: 34548479 Free PMC article. Clinical Trial.
Metastatic Colonization: Escaping Immune Surveillance.
Schaller J, Agudo J. Schaller J, et al. Among authors: agudo j. Cancers (Basel). 2020 Nov 16;12(11):3385. doi: 10.3390/cancers12113385. Cancers (Basel). 2020. PMID: 33207601 Free PMC article. Review.
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.
Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Waks AG, et al. Among authors: agudo j. J Immunother Cancer. 2022 Oct;10(10):e005119. doi: 10.1136/jitc-2022-005119. J Immunother Cancer. 2022. PMID: 36252998 Free PMC article. Clinical Trial.
68 results